The buy ratings keep piling in for ResMed. The post Citi slaps buy rating on ResMed shares appeared first on The Motley Fool ...

Shares of ResMed Inc. RMD advanced 3.29% to $232.44 Friday, on what proved to be an all-around positive trading session for ...

ResMed Inc.’s RMD growth in the second quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its Device sales continue to drive overall revenue growth. The company’s ...

A new survey finds that 33% of Singaporeans suffer from poor sleep—affecting productivity, relationships, and well-being.

RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fifteen research ...

Fintel reports that on March 5, 2025, Citigroup upgraded their outlook for ResMed Inc. - Depositary Receipt () (OTCPK:RSMDF) ...

This was the stock's third consecutive day of losses.

Highlights,Hedge funds and financial firms have adjusted their positions in ResMed, reflecting institutional activity.,The ...

Citi upgraded ResMed (RMD) to Buy from Neutral with a price target of A$44, up from A$41. The firm likes the stock’s “reasonable valuation, ...

Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...